107 results about "Membrane antigen" patented technology

Disclosed herein are isolated polypeptide and polypeptide complex compositions that comprise a first antigen recognizing molecule that binds to CD28 and a second antigen recognizing molecule that binds to prostate-specific membrane antigen (PSMA).

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-PSMA I&T or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a prostate-specific membrane antigen (PSMA)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligands having a glutamic acid-urea-lysine (GUL) moiety and a chelator that may include a radiometal.

The invention relates to a molecular probe for targeting a prostate specific membrane antigen and application, and belongs to the technical field of nuclear medicine. The invention provides a molecular probe for targeting a prostate specific membrane antigen, and the molecular probe successfully obtains a PSMA targeting molecular probe by introducing iodobenzene butyric acid and a PEG4 group on the basis of a PSMA-617 molecular structure on the basis of a double-ligand covalent coupling technology. The molecular probe has the advantages that the residence time of the molecular probe in a tumor area is obviously prolonged, the treatment effect is improved, the requirement for radioactive dose is reduced, and radiation damage to surrounding normal tissues is reduced; the specificity is excellent, a tumor area with high PSMA expression can be accurately targeted, and tumors with different PSMA expression levels can be effectively distinguished; the speed of reaching a target tumor is high, and an ideal imaging effect can be realized only in 20 minutes. In conclusion, the molecular probe has great advantages in diagnosis and treatment of PSMA high-expression tumors, and has high specificity and high efficiency.

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

The present invention discloses an antibody targeting prostate-specific membrane antigen, an antigen-binding fragment thereof, a preparation method and uses thereof. In the antibody or its antigen-binding fragment, the amino acid sequences of HCDR1, HCDR2 and HCDR3 are respectively as shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; and / or, the amino acid sequences of LCDR1, LCDR2 and LCDR3 are respectively as shown in SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9. The antibody can specifically bind to the extracellular domain protein of human and monkey PSMA, can effectively bind to C4-2 and 22RV1 cells, and the ADC containing the same can effectively kill tumor cell lines.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

To provide a method of synthesizing 2-(3{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid ([18F]DCFPyL), which is a radiotracer for prostate-specific membrane antigen (PSMA) PET imaging for prostate cancer.SOLUTION: A synthesis method comprises the following steps: (i) radiofluorinating a DCFPyL precursor comprising ester moiety-protecting groups to form a radiofluorinated DCPFPyL precursor; (ii) deprotecting the ester moiety-protecting groups of the radiofluorinated DCPFPyL precursor of the step (i) with phosphoric acid to form [18F]DCFPyL in a reaction mixture; and (iii) purifying the [18F]DCFPyL from the reaction mixture of the step (ii) to provide [18F]DCFPyL.SELECTED DRAWING: Figure 5

The present invention relates to small molecules having high affinity and specificity to prostrate-specific membrane antigen (PSMA) and methods of using them for therapeutic and diagnostic purposes.

Disclosed herein are isolated polypeptide and polypeptide complex compositions that comprise a prostate-specific membrane antigen (PSMA) binding domain that is linked to a peptide that impairs binding of the PSMA binding domain to PSMA.

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The present invention discloses a complex comprising (a) a compound, which is CA007 *, CA008 *, or CA009 *, or a pharmaceutically acceptable salt thereof, and (b) a radionuclide, which is selected from the group consisting of 203Pb and 212Pb. Also disclosed is the use of said complexes in the manufacture of a medicament for the treatment of cancers expressing prostate specific membrane antigen (PSMA). (CA007 *) (CA008 *) (CA009 *)

An anti-PSMA peptide includes an STMG (SEQ ID N0;2) motif or a structurally similar PSMA-binding variant thereof. The anti-PSMA peptide may be used as a targeting domain in, for example, a multi specific compound, chimeric antigen receptor (CAR) compound, a targeted immunotherapeutic compound, a targeted therapeutic compound, a targeted imaging compound, or as a capture moiety immobilized to a substrate in an assay device. Compounds that include the anti-PSMA peptide can be used in methods of treating a disease (e.g., cancer) in subject, methods of detecting cells that express PSMA, and / or methods of isolating cells that express PSMA.

Imaging and radiotherapeutic agents targeting fibroblast-activation protein-α (FAP-α) and / or prostate-specific membrane antigen (PSMA) and their use in imaging and treating FAP-α and / or PSMA-related diseases and disorders are disclosed.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

A prostate-specific membrane antigen (PSMA)-targeting ligand compound and a chelate thereof and use thereof are provided. The PSMA-targeting ligand compound has a structure as shown in formula I, where R1, R2 and R4 are each independently selected from the group consisting of H and optionally substituted linear or branched C1-C5 alkyl; R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is a sulfur atom or an oxygen atom; Y is selected from the group consisting of a chemical bond and —NH—(CH2)m-, where m is an integer selected from 0-18; and Z is a radioactive metal ion chelating group.

A method for imaging inflammation associated with inflammatory bowel disease (IBD) has been disclosed, which involves administering an imaging agent targeting prostate-specific membrane antigen (PSMA) to a subject and acquiring images.

Provided herein are, inter alia, methods of treating prostate cancer in a subject by administering to the subject a combination comprising i) a chimeric polypeptide targeting PSMA and CD3, and ii) an androgen receptor antagonist.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human prostate specific membrane antigen (PSMA) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody with the complementarity determining region sequence provided by the invention can specifically recognize PSMA expressed by cells and tissues, has good affinity in combination with the PSMA, has high recognition sensitivity, can effectively resist the interference of complex non-target protein components in the cells / tissues, has no specific combination with non-target antigens, is suitable for immunological detection of the PSMA, and has good application prospects. The kit is especially suitable for western blot detection and immunohistochemical methods, and can reduce the occurrence rate of false positive and false negative results and improve the accuracy of immunodiagnosis.

The present application relates to the technical field of medicine, in particular to a functional nanomaterial based on choline phosphate-cell membrane interaction and application thereof.The present application modifies manganese mineralized black phosphorus nanomaterial by bio-inspired polymer pGluCP adsorption, which retains the excellent biocompatibility and photothermal performance of BP, and at the same time, pGluCP enhances the 'chassis' effect of the material, captures tumor-related antigens, and can simultaneously capture water-soluble antigens and water-insoluble membrane antigens and form pathogen-like micro-nanoparticles, which is helpful for antigen delivery and APC presentation, and provides a feasible tool for capturing non-water-soluble membrane antigens, which is a major challenge.MnBP and pGluCP synergistically act, and can realize the personalized conversion of autologous tumors to vaccine production and delivery.

Disclosed herein are modified HIV envelope immunogens, engineered nanoparticle vaccines comprising modified HIV envelope immunogens and methods of use thereof for HIV vaccines.

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to an amino adipic acid-urea derivative containing L-proline and application of the amino adipic acid-urea derivative. The radioactive preparation obtained by labeling the amino-containing adipic acid-urea derivative with radionuclide has high uptake in tumors, meanwhile, the uptake in kidneys is effectively reduced, and the radioactive preparation is specifically combined with prostate specific membrane antigens and can be used as a novel tumor radioactive drug with popularization and application values for prostate cancer diagnosis.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

The present invention relates to a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq, and PET imaging of a patient, and a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq. The method allows for higher resolution images even at cancer sites with lower PSMA density, such as secondary lesions.

To provide prostate-specific membrane antigen (PSMA) ligands, and in particular, alternative multimodal PSMA ligands suitable for use as diagnostics and / or therapeutics.SOLUTION: The present disclosure provides PSMA ligands having: a glutamate-urea-lysine (GUL) moiety; a radioisotope; and a chelating agent that can comprise a radiometal.SELECTED DRAWING: None

Provided herein are, inter alia, antigen-binding molecules with binding specificity to cluster of differentiation 3 T cell receptor (CD3), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.

To provide modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity to prostate-specific membrane antigen (PSMA) (e.g., human PSMA).SOLUTION: The disclosure provides a modified immune cell, e.g., a modified T cell, comprising a CAR having affinity to PSMA, and a dominant-negative receptor and / or a switch receptor. The disclosure also provides a modified immune cell, e.g., a modified T cell, comprising a CAR having affinity to PSMA, and a dominant-negative receptor and / or a switch receptor, where the modified cell is capable of expressing and secreting a bispecific antibody.SELECTED DRAWING: Figure 1B

To provide novel radiolabeled compounds targeting PSMA, particularly compounds with low accumulation in salivary glands and / or kidneys.SOLUTION: Provided is a compound comprising a prostate-specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be -CO2H, -SO2H, -SO3H, -PO2H, or -PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases / conditions.SELECTED DRAWING: None

The invention discloses a method for overcoming tumor immune desert-type drug resistance by using a nano-carrier delivery vaccine. The method comprises the following steps: realizing targeted immune activation and microenvironment remodeling by constructing a three-stage structure collaborative delivery platform; the system comprises core-shell lipid nanoparticles (LNP) constructed based on a liposome self-assembly technology, mesoporous silica nanoparticles (MSNs) are adopted as a slow release module, and a manganese dioxide (MnO2) nano-cluster is anchored by a surface modified amino column [6] arene-lactose pyridine host-guest complex through a pi-pi accumulation effect; according to the present invention, through the dual targeting modification, the tumor cell membrane camouflage (retaining EGFR, CD44 and other membrane antigens) and the ApoA1 mimic peptide (22A peptide) synergistically act, the enrichment amount of the nanometer vaccine in the tumor tissue is 5.2 times of the normal liver tissue, and the problems that the traditional vaccine difficultly penetrates through the compact matrix of the immune desert type tumor and the lymph node activation efficiency is low are solved.